Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

Kyle Piskel

CFO

1 past transactions

Sequenta

Acquisition in 2015
Sequenta is a biotech company focused on developing clinical diagnostics that leverage a novel platform for assessing immune system status. Founded in 2008 by entrepreneurs with prior experience in the biotech sector, Sequenta aims to create innovative methods for measuring the immune cell receptor genes, which represent the most variable segment of the human genome. The advancements in DNA sequencing technology have enabled the company to devise unique approaches that can inform numerous clinical decisions through a single, powerful assay. By tapping into the genetic diversity of immune cell receptors, Sequenta addresses critical health conditions and disease management, positioning itself as a significant player in the field of clinical diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.